Sobo & Sobo:
We’re Winners
at Your Side.

Related Items

Free Case Evaluation

New York Xarelto Lawsuit Lawyer

At one time, Xarelto (Rivaroxaban) was considered to be a ground breaker when treating patients with atrial fibrillation and other heart-related issues.  The beauty of its use lay in the fact that users only have to take one pill a day and do not need to have their International Normalizing Ratio (INR) taken constantly, as users taking warfarin do.  Today however the story is changing, the number of Xarelto lawsuits being filed across the country and in Canada is growing.

Once the U.S. Food and Drug Administration (FDA) approved Xarelto in 2011 it was prescribed to millions every year. Xarelto, manufactured by Bayer and Janssen Pharmaceuticals, a division of Johnson & Johnson (J&J), was approved for preventing deep vein thrombosis, blood clots, traveling blood clots and diminishing the risk of stroke. As time passed, it became apparent that Xarelto had very serious side effects and because there was no antidote to reverse those effects tragically, some patients died because doctors could not stop the bleeding.

If you or a loved one has experienced harmful side effects from taking Xarelto, Sobo & Sobo is here to help. We understand how frightening must be to trust that the drug your doctor prescribed is going to help you, and then you find out it has the potential to seriously harm or kill you. We want to hear your story and will be with you every step of the way.  Sobo & Sobo will work to get the results you deserve and looks forward to winning together.

The Trouble With Xarelto

Blood coagulation depends on Vitamin K to produce the clotting agent thrombin. Warfarin disables but does not prevent production of Vitamin K, so serious bleeding can be stopped with high dosages of Vitamin K.  Xarelto, however, prevents production of Vitamin K. If a patient is hemorrhaging, there is no antidote to stop or reverse it.

The FDA apparently received 680 adverse event reports in the United States regarding Xarelto users in 2013 and in Germany, Bayer’s homeland, it was reported that, between January 2012 and September 2013, Xarelto was linked to 130 deaths and with 1,700 serious complications.

Xarelto turned into a money making drug for the company, racking up over $2 billion in sales in 2016, and by September 2017, reports indicate the drug made J&J $1.8 billion in the nine-month time frame in spite of the drug’s health risks and more lawsuits being filed.

According to the FDA, nearly 22,000 severe injuries, including more than 3,000 deaths were recorded due to anticoagulant use in 2016. The Centers for Disease Control and Prevention (CDC) also reported that blood thinners were among the most dangerous drugs, accounting for more E.R. trips than any other class of drugs.

In December 2006 a clinical trial, referred to as An Efficacy and Safety Study of Rivaroxaban With Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Patients With Non-Valvular Atrial Fibrillation or ROCKET AF for short, was compromised due to a faulty blood-testing device.

In 2014, Johnson & Johnson revealed that the device used in the ROCKET AF trial, the INRatio, had been recalled for understating the risk of bleeding. The question arose whether or not trial participants received an incorrect dose of warfarin and had more severe side effects, which made Xarelto look more effective and safer.

Since that startling revelation, the FDA has insisted that the drug makers update their black box warning labels five times from 2013 to 2016 as consumers were not adequately warned about all potential side effects of Xarelto.

Black Box Label Warnings Added for Xarelto

August 2013 – Warning of increased risk of spinal bleeds

January 2014 – Two warnings added:

  • Not to be used by patients with prosthetic heart valves.
  • No known antidote to reverse bleeding.

March 2014 –  Additional information added for healthcare professionals on limiting spinal bleeds

December 2014 – New adverse reactions added:

  • Thrombocytopenia
  • Hepatitis

May 2016 – Increased bleeding risk for those taking SSRI and SNRI antidepressants

Xarelto Linked to Numerous Complications

  • Lack of an antidote to reverse uncontrolled life-threatening bleeding
  • Severe internal hemorrhaging
  • Severe brain bleeding
  • Spinal bleeds
  • Hepatitis
  • Thrombocytopenia
  • Increased bleeding risk with SNRI and SSRI antidepressants
  • Strokes
  • Intestinal bleeding
  • Rectal bleeding
  • Blood clots
  • Pulmonary embolism
  • Deep vein thrombosis
  • Arrhythmia
  • Tachycardia
  • Sudden drastic changes in blood pressure
  • Tingling/itching sensations on skin
  • Numbness
  • Back pain
  • Bladder problems
  • Difficulty swallowing
  • Headaches
  • Dizziness
  • Pain or weakness in extremities
  • Fainting
  • Muscle spasms
  • Death
  • Excessive loss of blood
  • Adrenal bleeding
  • Retinal hemorrhages
  • Abdominal hemorrhages
  • Epidural hematoma
  • Wound infection/complications

Lawsuits Numbers Are Rising

To date the number of lawsuits filed relating to Xarelto have been rapidly increasing and Johnson & Johnson refuses to offer any settlements, vowing to appeal each case it loses.

If you or a loved one has experienced serious complications after taking this drug, it is vitally important that you find out what your legal rights are by seeking an experienced medical malpractice, defective drug attorney. Make certain to contact an attorney sooner, rather than later, as each state has its own statute of limitations and other applicable deadlines that may affect your ability to obtain compensation if you wait.

The attorneys at Sobo & Sobo are personal injury law leaders with extensive experience in all types of defective drug litigation. During your initial consultation we listen to your story, and help you make informed decisions about how to proceed.

Call Sobo & Sobo at 855-468-7626 as soon as possible.  We are eager to hear your story.  Our prompt action, could make a difference in the outcome of your case. We would be honored to hear from you and look forward to taking the next step toward Winning Together.